Form 4: Guardant Health Executive John G. Saia Reports Stock Option and Restricted Stock Unit Awards
SEC Form 4 Filing
John G. Saia, Chief Legal Officer of Guardant Health, Inc., reports the acquisition of stock options and restricted stock units.
Summary
- On March 12, 2025, John G. Saia, the Chief Legal Officer of Guardant Health, Inc., was granted stock options for 26,799 shares at an exercise price of $43.10.
- These options vest over a three-year period, with 33% vesting on April 1, 2026, and the remaining 67% vesting in equal monthly installments over the subsequent two years.
- Saia also received 17,866 restricted stock units (RSUs) that vest over a three-year period.
- Similar to the stock options, 33% of the RSUs vest on April 1, 2026, with the remaining 67% vesting in equal quarterly installments over the following two years.
- Following these transactions, Saia directly owns 26,799 stock options and 17,866 RSUs.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral-positive signal.
Positives
- The granting of stock options and RSUs to the Chief Legal Officer aligns his interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the executive.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance.
Industry Context
Stock option and RSU grants are common practices in the biotech industry to incentivize and retain key executives.
Comparison to Industry Standards
- Executive compensation packages, including stock options and RSUs, are standard practice among publicly traded biotech companies like Guardant Health.
- Companies such as Illumina, Exact Sciences, and Foundation Medicine also utilize similar equity-based compensation to align executive interests with shareholder value.
- The vesting schedules are typical, designed to encourage long-term commitment and performance.
Stakeholder Impact
- Shareholders: The equity grants align management's interests with shareholder value.
- Employees: The grants can serve as a positive signal regarding the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 03/12/2025 | Date of stock option and restricted stock unit awards. |
| 03/13/2025 | Date of signature on the Form 4 filing. |
| 04/01/2026 | Date when 33% of the stock options and restricted stock units vest. |
| 03/12/2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.